GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Sale Of Property, Plant, Equipment

QURE (uniQure NV) Sale Of Property, Plant, Equipment : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Sale Of Property, Plant, Equipment?

uniQure NV's sale of property, plant, equipment for the three months ended in Sep. 2024 was $0.00 Mil. It means uniQure NV gained $0.00 Mil from selling property, plant, and equipment. uniQure NV's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Jun. 2024 ), uniQure NV gained the same money from selling property, plant, and equipment in Sep. 2024 ($0.00 Mil).

uniQure NV Sale Of Property, Plant, Equipment Historical Data

The historical data trend for uniQure NV's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV Sale Of Property, Plant, Equipment Chart

uniQure NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

uniQure NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

uniQure NV Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

uniQure NV Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of uniQure NV's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

uniQure NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Sale Of Property, Plant, Equipment
Comparable Companies
PGEN RPHM FUSN KALV AVTE MGTX JANX AVIR THRD VIGL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0EE0:UK UQ1:Germany
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
Website
https://www.uniqure.com
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Executives
Walid Abi-saab officer: Chief Medical Officer C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Pierre Caloz officer: Chief Operating Officer UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Christian Klemt officer: Chief Financial Officer PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Madhavan Balachandran director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Gut director C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post director
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Jeremy P. Springhorn director C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Matthew C Kapusta director, officer: CEO, Managing Director 7358 MCVAY ROAD, GERMANTOWN TN 38138
Ricardo Dolmetsch officer: President, R&D 113 HARTWELL AVENUE, LEXINGTON MA 02421
Kuta Alexander Edward Iii officer: Executive VP, Operations 239 WILLIS ROAD, SUDBURY MA 01776